CDK4 and cancer: Nevertheless, while some studies suggest that pro‐inflammatory and pro‐angiogenic SASP can enhance immune surveillance by NK cells [71], and improve the delivery of chemotherapeutic drugs [70], respectively, more research is needed to determine which types of chemotherapeutic agents (DNA‐damaging agents vs. CDK4/6i) can induce cancer cell senescence with more robust anti‐tumor immunomodulating capabilities.